Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study

por Kim, Dong-Wook, Saussele, Susanne, Williams, Loretta A., Mohamed, Hesham, Rong, Yuanxin, Zyczynski, Teresa, Pinilla-Ibarz, Javier, Abruzzese, Elisabetta
Publicado 2018